- Home
- PLX vs DLNG Comparison
PLX vs DLNG Comparison
Compare PLX & DLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- DLNG
- Stock Information
- Founded
- PLX 1993
- DLNG 2013
- Country
- PLX United States
- DLNG Greece
- Employees
- PLX N/A
- DLNG N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- DLNG Marine Transportation
- Sector
- PLX Health Care
- DLNG Consumer Discretionary
- Exchange
- PLX Nasdaq
- DLNG Nasdaq
- Market Cap
- PLX 122.6M
- DLNG 129.0M
- IPO Year
- PLX 1998
- DLNG 2013
- Fundamental
- Price
- PLX $1.46
- DLNG $3.53
- Analyst Decision
- PLX Strong Buy
- DLNG
- Analyst Count
- PLX 1
- DLNG 0
- Target Price
- PLX $15.00
- DLNG N/A
- AVG Volume (30 Days)
- PLX 1.3M
- DLNG 33.6K
- Earning Date
- PLX 08-13-2025
- DLNG 09-09-2025
- Dividend Yield
- PLX N/A
- DLNG 5.51%
- EPS Growth
- PLX N/A
- DLNG 53.29
- EPS
- PLX 0.05
- DLNG 1.10
- Revenue
- PLX $59,764,000.00
- DLNG $157,455,000.00
- Revenue This Year
- PLX $65.02
- DLNG N/A
- Revenue Next Year
- PLX $57.34
- DLNG $0.37
- P/E Ratio
- PLX $30.21
- DLNG $3.25
- Revenue Growth
- PLX 0.18
- DLNG N/A
- 52 Week Low
- PLX $0.82
- DLNG $3.18
- 52 Week High
- PLX $3.10
- DLNG $5.65
- Technical
- Relative Strength Index (RSI)
- PLX 46.02
- DLNG 44.81
- Support Level
- PLX $1.36
- DLNG $3.52
- Resistance Level
- PLX $1.54
- DLNG $3.69
- Average True Range (ATR)
- PLX 0.08
- DLNG 0.10
- MACD
- PLX 0.02
- DLNG -0.00
- Stochastic Oscillator
- PLX 41.67
- DLNG 17.39
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About DLNG Dynagas LNG Partners LP Common Units
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.